Explore the words cloud of the HEPASPHER project. It provides you a very rough idea of what is the project "HEPASPHER" about.
The following table provides information about the project.
|Coordinator Country||Sweden [SE]|
|Total cost||2˙413˙449 €|
|EC max contribution||2˙413˙449 € (100%)|
1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
|Duration (year-month-day)||from 2017-09-01 to 2022-08-31|
Take a look of project's partnership.
|1||KAROLINSKA INSTITUTET||SE (STOCKHOLM)||coordinator||2˙413˙449.00|
The liver is a vital organ for synthesis and detoxification. The most significant liver diseases are hepatitis, non alcoholic fatty liver disease (NAFLD), non-alcoholic fatty liver steatohepatitis (NASH), carcinoma and cirrhosis. An additional and important cause of liver injury is adverse drug reactions (ADRs). In particular NAFLD is the most common liver disease affecting between 20% and 44% of European adults and 43-70% of patients with type 2 diabetes, and is one prime cause for chronic and end-stage liver disease, such as cirrhosis and primary hepatocellular carcinoma. This proposal is based on recent findings in the laboratory: The development of novel 3D spheroid system with chemically defined media allowing studies of chronic drug toxicity, relevant liver disease and liver function for 5 weeks in vitro, the finding of the role of miRNA in hepatocyte dedifferentiation and that hepatocytes during spheroid formation first de-differentiate but later in spheroids re-differentiate to an in vivo relevant phenotype. This forms the basis for the main objectives: i) to study diseased liver in vitro with identification of mechanisms, biomarkers and novel drug candidates for treatment of NAFLD and fibrosis, ii) evaluate drug toxicity sensitivity and mechanisms in diseased liver systems and iii) further develop methods for hepatocyte proliferation and regeneration in vitro for transplantation purposes, including genetic editing in cases of hepatocytes obtained from patients with genetically inherited liver diseases.
This work is carried out in close contact with the Hepatology unit at the Karolinska Hospital partly using resources at the Science for Life Laboratory at Karolinska. It is anticipated that the project can provide with novel mechanisms, biomarkers and new targets for treatment of liver disease as well as novel methods for clinically applicable liver regeneration without the use of stem cells or transformed cells.
|year||authors and title||journal||last update|
Volker M. Lauschke, Reza Zandi Shafagh, Delilah F. G. Hendriks, Magnus Ingelmanâ€Sundberg
3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism and toxicity: Emerging culture paradigms and applications
published pages: 1800347, ISSN: 1860-6768, DOI: 10.1002/biot.201800347
Volker M. Lauschke, Yitian Zhou, Magnus Ingelman-Sundberg
Novel genetic and epigenetic factors of importance for inter-individual differences in drug disposition, response and toxicity
published pages: , ISSN: 0163-7258, DOI: 10.1016/j.pharmthera.2019.01.002
|Pharmacology & Therapeutics||2019-05-22|
Catherine C Bell, Anita C A Dankers, Volker M Lauschke, Rowena Sison-Young, Roz Jenkins, Cliff Rowe, Chris E Goldring, Kevin Park, Sophie L Regan, Tracy Walker, Chris Schofield, Audrey Baze, Alison J Foster, Dominic P Williams, Amy W M van de Ven, Frank Jacobs, Jos van Houdt, Tuula LÃ¤hteenmÃ¤ki, Jan Snoeys, Satu Juhila, Lysiane Richert, Magnus Ingelman-Sundberg
Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-term Toxicity Applications: A Multicenter Study
published pages: 655-666, ISSN: 1096-6080, DOI: 10.1093/toxsci/kfx289
|Toxicological Sciences 162/2||2019-05-22|
Isabel Cordero-Herrera, Mikael Kozyra, Zhengbing Zhuge, Sarah McCann Haworth, Chiara Moretti, Maria Peleli, Mayara Caldeira-Dias, Arghavan Jahandideh, Han Huirong, Josiane de Campos Cruz, Andrei L. Kleschyov, Marcelo F. Montenegro, Magnus Ingelman-Sundberg, Eddie Weitzberg, Jon O. Lundberg, Mattias Carlstrom
AMP-activated protein kinase activation and NADPH oxidase inhibition by inorganic nitrate and nitrite prevent liver steatosis
published pages: 217-226, ISSN: 0027-8424, DOI: 10.1073/pnas.1809406115
|Proceedings of the National Academy of Sciences 116/1||2019-05-22|
Sabine U Vorrink, Yitian Zhou, Magnus Ingelman-Sundberg, Volker M Lauschke
Prediction of Drug-Induced Hepatotoxicity Using Long-Term Stable Primary Hepatic 3D Spheroid Cultures in Chemically Defined Conditions
published pages: 655-665, ISSN: 1096-6080, DOI: 10.1093/toxsci/kfy058
|Toxicological Sciences 163/2||2019-05-22|
Are you the coordinator (or a participant) of this project? Plaese send me more information about the "HEPASPHER" project.
For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.
Send me an email (firstname.lastname@example.org) and I put them in your project's page as son as possible.
Thanks. And then put a link of this page into your project's website.
The information about "HEPASPHER" are provided by the European Opendata Portal: CORDIS opendata.